PubMed HealthSearch

Biomedical subjects

R Halder

Publications and source records attributed to R Halder.

4 recordsLinked to original sources

Systemic growth hormone does not affect human sleep.

Subsequent to sleep onset, GH concentrations increase markedly, suggesting a stimulatory influence of sleep on GH secretion. However, results have been inconsistent as to whether GH conversely exerts a significant influence on sleep. Hence, the effects of exogenous administration of GH and of GH secretion stimulated by GH-releasing hormone (GHRH) on sleep were reexamined in 3 experiments in healthy male volunteers. In Exp I, 12 men participated on 3 experimental nights, receiving a constant iv infusion of 5 IU GH (between 2100-0700 h), an im bolus injection of 5 IU GH at 2100 h, and placebo. In Exp II, the effects of a short iv infusion of a high dose of 48 IU GH (between 2345-2315 h) on sleep were evaluated in 3 men. In Exp III, the effects of continuous infusion of 30 micrograms/h GHRH (between 2200-0700 h) on sleep were compared to the placebo condition in 10 men. Experiments were double blind, within-subject, cross-over comparisons and included an adaptation night before experimental nights. On all nights, the subjects went to bed at 2300 h and were awakened at 0700 h. Administration of GH elevated plasma GH and somatomedin-C levels throughout the night (P < 0.005). Neither im administration of 5 IU GH nor iv administration of 5 and 48 IU GH had any effect on the total sleep time or the time spent in different sleep stages during the whole night or in the first and second halves of sleep time. Infusion of GHRH increased nocturnal GH secretion (P < 0.005), but the episodic pattern of GH secretion was maintained. However, sleep remained unchanged during GHRH infusion. From these results we conclude that in healthy man, systemic GH has no physiological role for sleep regulation.

Adult

Melagenina. An analysis of published and other available data.

The placenta should be an excellent source of factors which might be efficacious in the treatment of vitiligo. Proof, however, for that hypothesis is lacking. Numerous claims have been made about Melagenina. It would appear to be nontoxic if we were to assume that the medication does not contain infectious agents. The ease of application certainly is of value for patients with vitiligo who wish to try some therapy for their disease. Practically, it is very costly to travel to Cuba and to export Melagenina. The cost of shipping on airplanes plus import duties make the price very high. Unfortunately, the inconvenience of the travel and the costs cannot necessarily be offset by the claims to efficacy. The biochemistry, assays for biological activity and the pharmacology studies as reported do not stand up to rigorous and acceptable scientific standards. The medication clearly needs further and intensive study. Now that the barriers between countries are being dismantled, it is hoped that the Cuban team will be able to travel to other laboratories outside of Cuba where they can continue animal studies as well as studies on melanocytes growing in culture. In addition, it is hoped that they will be able to share more about the pharmacology, the chemistry, the isolation and other chemical properties of the medication. These results can be published and will stand up to scrutiny by the world's medical and scientific community. Until that time, patients and their physicians must recognize the uncertain quality of the claims as well as the high financial cost and potential risk of using Melagenina either within or outside of Cuba.

Cuba

Alkaptonuria.

Explore the source record for details and available documents.

Adult

Determination of optimal topical photochemotherapy for vitiligo.

The efficacy of topical 8-methoxypsoralen (8-MOP) in varying concentrations and vehicles was assessed in 73 vitiligo patients. The response rates in different anatomic sites were also assessed. Seven patients (9%) had 100% repigmentation; 26 (36%) had 50% or greater repigmentation, 29 (40%) had some degree of pigment return, but less than 50%; 11 (15%) had no repigmentation. Results suggest that neither concentration of drug nor vehicle is a crucial factor for inducing repigmentation of vitiliginous patches on the face, trunk, and extremities. Low-dose 8-MOP (0.1%) was as effective as high dose 8-MOP (0.5%, 1%), while causing fewer side effects. However, when treating recalcitrant areas (distal extremities), 1% 8-MOP may be the most efficacious preparation for topical photochemotherapy. A phototoxic response preceded repigmentation in all cases. The following responses were obtained for the various anatomic sites treated: 56% of facial lesions; 35% of trunk areas; 36% of the extremities, and 13% of the recalcitrant areas had greater than 50% repigmentation.

Administration, Topical